Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Alcohol use and HIV suppression after completion of financial incentives for alcohol abstinence and isoniazid adherence: a randomized controlled trial.
EClinicalMedicine
February 2025
Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Background: In a recent randomized trial, six months of financial incentives contingent for recent alcohol abstinence led to lower levels of hazardous drinking, while incentives for recent isoniazid (INH) ingestion had no impact on INH adherence, during TB preventive therapy among persons with HIV (PWH). Whether the short-term incentives influence long-term alcohol use and HIV viral suppression post-intervention is unknown.
Methods: We analyzed twelve-month HIV viral suppression and alcohol use in the Drinkers' Intervention to Prevent Tuberculosis study, a randomized controlled trial among PWH with latent TB and unhealthy alcohol use in south-western Uganda.
Pharmacokinetic Analysis of an Isoniazid Suspension Among Spanish Children Under 6 Years of Age.
Antibiotics (Basel)
January 2025
Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatria, Servei d'Infectologia, Institut de Recerca Pediàtrica Sant Joan de Déu, 08950 Barcelona, Spain.
: Isoniazid (INH) remains a first-line drug for the treatment of tuberculosis (TB) in young children. In 2010, the WHO recommended an increase in the daily dose of INH up to 10 (7-15) mg/kg. Currently, there are no INH suspensions available in Europe.
View Article and Find Full Text PDFIndirect treatment comparison of lanadelumab and a C1-esterase inhibitor in pediatric patients with hereditary angioedema.
J Comp Eff Res
February 2025
ICON plc, Insights, Evidence & Value - Health Economics & Epidemiology, Langen, Germany.
To compare the efficacy and safety of lanadelumab versus other approved long-term prophylaxis (LTP) treatments in patients with pediatric hereditary angioedema (HAE) aged <12 years. A systematic literature review was conducted to identify studies of LTP in patients with HAE aged <12 years. Two studies met the inclusion criteria in an indirect treatment comparison of efficacy and safety data in pediatric HAE patients.
View Article and Find Full Text PDFAngioedema due to acquired C1-inhibitor deficiency without hematological condition: a multicenter French cohort study of 34 patients.
J Allergy Clin Immunol Pract
January 2025
Sorbonne Université, service de médecine interne, AP-HP, Hôpital Saint Antoine, F-75012 Paris, France. Electronic address:
Background: Angioedema (AE) due to acquired C1-inhibitor deficiency (AAE-C1-INH) is a rare disease associating recurrent edema of mucosa and skin. Several underlying diseases have been reported, mainly lymphoproliferative diseases and monoclonal gammopathy. However, 15 to 20% of patients never exhibit such a hematological condition.
View Article and Find Full Text PDF[Hereditary angioedema type 1, limitations for prophylactic therapy with Lanadelumab: Regarding a case].
Rev Alerg Mex
December 2024
Médica general, Facultad de Ciencias de la Salud, Universidad Militar Nueva Granada, Hospital Universitario Mayor Méderi, Colombia.
Article Synopsis
- Hereditary Angioedema (HAE) is a rare autosomal dominant disorder characterized by low levels or dysfunctional C1 inhibitor, leading to recurrent episodes of swelling and abdominal pain.
- A reported case involves a 53-year-old man with a longstanding history of recurrent edema and family history, who showed low levels of plasma proteins but faced treatment challenges despite various therapies, including a trial of Lanadelumab for prophylaxis.
- The patient's experience highlights issues in managing HAE, revealing an adverse reaction to Lanadelumab that is not commonly documented, emphasizing the need for better-informed treatment strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!